Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Douglas L. Arnold et al.|The Lancet Neurology|2021Cited by 192
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130
Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glanceMd. Mominur Rhaman, Rohit Sharma, Md. Rezaul Islam et al.|Frontiers in Cell and Developmental Biology|2022Cited by 58
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and ProgressionMarianna Cortese, Tuula Pirttilä, Xiaojing Peng et al.|Neurology|2025Cited by 3